Johnson & Johnson (NYSE:JNJ) Shares Sold by Cassady Schiller Wealth Management LLC

Cassady Schiller Wealth Management LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 1.1% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 8,026 shares of the company’s stock after selling 88 shares during the quarter. Cassady Schiller Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,301,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Sather Financial Group Inc increased its position in Johnson & Johnson by 37.8% during the 3rd quarter. Sather Financial Group Inc now owns 2,756 shares of the company’s stock worth $447,000 after purchasing an additional 756 shares during the period. Schear Investment Advisers LLC grew its holdings in Johnson & Johnson by 6.9% during the third quarter. Schear Investment Advisers LLC now owns 4,711 shares of the company’s stock worth $763,000 after acquiring an additional 304 shares during the period. Accredited Investors Inc. raised its position in Johnson & Johnson by 4.0% in the third quarter. Accredited Investors Inc. now owns 7,901 shares of the company’s stock worth $1,280,000 after acquiring an additional 301 shares in the last quarter. Seizert Capital Partners LLC lifted its holdings in Johnson & Johnson by 1.0% in the third quarter. Seizert Capital Partners LLC now owns 244,057 shares of the company’s stock valued at $39,552,000 after acquiring an additional 2,441 shares during the period. Finally, Kinsale Capital Group Inc. boosted its position in shares of Johnson & Johnson by 16.8% during the 3rd quarter. Kinsale Capital Group Inc. now owns 44,251 shares of the company’s stock worth $7,171,000 after purchasing an additional 6,381 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent analyst reports. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Royal Bank of Canada lifted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Guggenheim upped their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Finally, Citigroup upped their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $175.94.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $154.00 on Friday. The company has a market capitalization of $370.77 billion, a price-to-earnings ratio of 22.29, a PEG ratio of 2.74 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company’s 50 day simple moving average is $161.35 and its 200 day simple moving average is $156.10.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter last year, the firm earned $2.66 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. On average, sell-side analysts predict that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.22%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.